CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it and Sanofi US have mutually agreed to terminate their agreement for commercialization of the investigational products, PA8140 and PA32540 effective November 29, 2014. As of the effective date of the termination, all licenses granted to Sanofi US will be terminated and all rights to the products will revert to POZEN.
Help employers find you! Check out all the jobs and post your resume.
